Expand GLMD Menu
GLMD MENU

GLMD Latest Press Releases

-- July 28, 2026 --

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market PRNewswire 7:00 AM

-- July 16, 2026 --

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol PRNewswire 7:30 AM

-- June 22, 2026 --

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition PRNewswire 7:00 AM

-- June 8, 2026 --

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market PRNewswire 8:11 AM

-- June 2, 2026 --

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis PRNewswire 7:30 AM

-- May 14, 2026 --

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg PRNewswire 7:30 AM

-- May 6, 2026 --

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics PRNewswire 5:25 PM

-- April 14, 2026 --

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers PRNewswire 7:30 AM

-- April 9, 2026 --

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol PRNewswire 7:30 AM

-- March 31, 2026 --

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 PRNewswire 4:15 PM
Market Data Delayed 15 Minutes